Impact of the faecal immunochemical test on colorectal cancer survival

María Angeles Gutierrez-Stampa, Vanessa Aguilar, Cristina Sarasqueta, Joaquín Cubiella, Isabel Portillo, Luis Bujanda, María Angeles Gutierrez-Stampa, Vanessa Aguilar, Cristina Sarasqueta, Joaquín Cubiella, Isabel Portillo, Luis Bujanda

Abstract

Background: There is already evidence that the faecal immunochemical test (FIT) is a useful tool for the diagnosis of colorectal cancer (CRC) that helps to identify symptomatic patients requiring early colonoscopy. Although the recommendation to use FIT is widely accepted, there are no data concerning whether this strategy improves patient survival.The objective was to assess whether the survival is higher if CRC patients have been first diagnosed by FIT (as compared with the rest of patients with CRC).

Methods: We identified all cases of CRC diagnosed between 2009 and 2016 in Donostialdea (Spain), excluding all the CRC detected in population screening. We focused on symptomatic patients. One thousand five hundred twenty-seven cases of CRC were divided into two groups based on the route to diagnosis: group 1: individuals who tested positive in a FIT during the year before diagnosis, and group 2: others.Survival was assessed by Kaplan-Meier estimation, and with the log-rank test. A Cox regression model was used to adjust for differences between groups due to other variables associated with survival.

Results: One thousand nine hundred sixty-seven cases of invasive CRC were identified, of which 22.4% were detected in population screening. Of the 1527 cases diagnosed in symptomatic patients, 317 patients had undergone a FIT in the year before the diagnosis of CRC. In 279 cases(18.3%), the result had been positive and this was the first step towards their CRC diagnosis (group 1). Group 2 was composed of the 1248 cases of CRC (81.7%). Considering these cases, 1210 patients with CRC did not undergo any FIT while 38 patients presented a negative result in the year before the diagnosis. The rate of early-stage disease (stage I or II) was higher in group 1 (51.3% vs 45.5% in group 2) (p = 0.04). Furthermore, the 3-year survival was longer in group 1 (72% vs 59% in group 2) (HR 1.50; 95% CI 1.22-1.84).The variables independently associated with worse survival were: group 2, age > 70 years and stage at the moment of diagnosis.

Conclusions: The use of FIT as a diagnostic strategy in symptomatic patients may improve survival in CRC. Nonetheless,FIT is still not widely used in our region.

Keywords: Colorectal cancer; Faecal immunochemical test; Survival.

Conflict of interest statement

The authors declare that they have no “competing interests” in this section.

Figures

Fig. 1
Fig. 1
Flow of patients with colorectal cancer (CRC) though the study
Fig. 2
Fig. 2
Distribution of stage of colorectal cancer by groups .Group 1: with positive faecal immunochemical test results in the previous 12 months. Group 2: patients that either did not performed any FIT in the previous 12 months before diagnosis or display a negative FIT
Fig. 3
Fig. 3
Kaplan-Meier overall survival curves by group with 95% confidence intervals and numbers at risk. Group 1: with positive faecal immunochemical test results in the previous 12 months. Group 2: patients that either did not performed any FIT in the previous 12 months before diagnosis or display a negative FIT

References

    1. GLOBOCAN. Global Cancer Observatory: Cancer Today [Internet]. Lyon: International Agency for research on Cancer [cited 2019 Feb 20]. Available from: .
    1. National Institute for Health and Care Excellence (NICE) Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care | Diagnostics guidance DG30. 2017.
    1. Fitzpatrick-Lewis D, Ali MU, Warren R, Kenny M, Sherifali D, Raina P. Screening for Colorectal Cancer: A Systematic Review and Meta-Analysis. Clin Colorectal Cancer. 2016;15(4):298–313. doi: 10.1016/j.clcc.2016.03.003.
    1. Jellema P, van der Windt DA, Bruinvels DJ, Mallen CD, van Weyenberg SJ, Mulder CJ, et al. Value of symptoms and additional diagnostic tests for colorectal cancer in primary care: systematic review and meta-analysis. BMJ. 2010;340:c1269. doi: 10.1136/bmj.c1269.
    1. Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med. 2014;160(3):171. doi: 10.7326/M13-1484.
    1. Katsoula A, Paschos P, Haidich AB, Tsapas A, Giouleme O. Diagnostic Accuracy of Fecal Immunochemical Test in Patients at Increased Risk for Colorectal Cancer: A Meta-analysis. JAMA Intern Med. 2017;177(8):1110–1118. doi: 10.1001/jamainternmed.2017.2309.
    1. Cubiella J, Salve M, Díaz-Ondina M, Vega P, Alves MT, Iglesias F, et al. Diagnostic accuracy of the faecal immunochemical test for colorectal cancer in symptomatic patients: comparison with NICE and SIGN referral criteria. Colorectal Dis. 2014;16(8):O273–O282. doi: 10.1111/codi.12569.
    1. Rodríguez-Alonso L, Rodríguez-Moranta F, Ruiz-Cerulla A, Lobatón T, Arajol C, Binefa G, et al. An urgent referral strategy for symptomatic patients with suspected colorectal cancer based on a quantitative immunochemical faecal occult blood test. Dig Liver Dis. 2015;47(9):797–804. doi: 10.1016/j.dld.2015.05.004.
    1. Quyn AJ, Steele RJ, Digby J, Strachan JA, Mowat C, McDonald PJ, et al. Application of NICE guideline NG12 to the initial assessment of patients with lower gastrointestinal symptoms: not FIT for purpose? Ann Clin Biochem. 2018;55(1):69–76. doi: 10.1177/0004563217707981.
    1. Zorzi M, Fedeli U, Schievano E, Bovo E, Guzzinati S, Baracco S, et al. Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test. Gut. 2015;64(5):784–790. doi: 10.1136/gutjnl-2014-307508.
    1. Idigoras I, Arrospide A, Portillo I, Arana-Arri E, Martínez-Indart L, Mar J, et al. Evaluation of the colorectal cancer screening Programme in the Basque Country (Spain) and its effectiveness based on the Miscan-colon model. BMC Public Health. 2017;18(1):78. doi: 10.1186/s12889-017-4639-3.
    1. Westwood M, Lang S, Armstrong N, van Turenhout S, Cubiella J, Stirk L, et al. Faecal immunochemical tests (FIT) can help to rule out colorectal cancer in patients presenting in primary care with lower abdominal symptoms: a systematic review conducted to inform new NICE DG30 diagnostic guidance. BMC Med. 2017;15(1):189. doi: 10.1186/s12916-017-0944-z.
    1. Pin Vieito N, Zarraquiños S, Cubiella J. High-risk symptoms and quantitative faecal immunochemical test accuracy: Systematic review and meta-analysis. World J Gastroenterol. 2019;25(19):2383–2401. doi: 10.3748/wjg.v25.i19.2383.
    1. Digby J, Steele RJ, Strachan JA, Mowat C, Anderson AS, McCann R, et al. Do other variables add value to assessment of the risk of colorectal disease using faecal immunochemical tests for haemoglobin? Ann Clin Biochem. 2019;56(4):472–479. doi: 10.1177/0004563219839423.
    1. Cubiella J, Marzo-Castillejo M, Mascort-Roca JJ, Amador-Romero FJ, Bellas-Beceiro B, Clofent-Vilaplana J, et al. Clinical practice guideline. Diagnosis and prevention of colorectal cancer. 2018 Update. Gastroenterol Hepatol. 2018;41(9):585–596. doi: 10.1016/j.gastrohep.2018.07.012.
    1. Edge S, Byrd DR, Compton CC, Fritz AG, Greene F, Trotti A. AJCC Cancer Staging Manual. 7. New York: Springer; 2010.
    1. Gutiérrez-Stampa MA, Aguilar Gama V, Bujanda L. Utility of faecal occult blood test for the diagnosis of colorectal cancer in clinical practice in primary care. Aten Primaria. 2019; In press. [PMID: 31582188. 10.1016/j.aprim.2019.07.009.
    1. Lyratzopoulos G, Wardle J, Rubin G. Rethinking diagnostic delay in cancer: how difficult is the diagnosis? BMJ. 2014;349:g7400. doi: 10.1136/bmj.g7400.
    1. Esteva M, Leiva A, Ramos M, Pita-Fernández S, González-Luján L, Casamitjana M, et al. Factors related with symptom duration until diagnosis and treatment of symptomatic colorectal cancer. BMC Cancer. 2013;13:87. doi: 10.1186/1471-2407-13-87.
    1. Tørring ML, Frydenberg M, Hansen RP, Olesen F, Hamilton W, Vedsted P. Time to diagnosis and mortality in colorectal cancer: a cohort study in primary care. Br J Cancer. 2011;104(6):934–940. doi: 10.1038/bjc.2011.60.
    1. Mansouri D, McMillan DC, Crearie C, Morrison DS, Crighton EM, Horgan PG. Temporal trends in mode, site and stage of presentation with the introduction of colorectal cancer screening: a decade of experience from the West of Scotland. Br J Cancer. 2015;113(3):556–561. doi: 10.1038/bjc.2015.230.
    1. Koïvogui A, Balamou C, Rymzhanova R, Letrung T, Hadad HA, Brixi Z, et al. Colorectal cancer fecal screening test completion after age 74, sources and outcomes in French program. World J Gastrointest Oncol. 2019;11(9):729–740. doi: 10.4251/wjgo.v11.i9.729.
    1. Godber IM, Benton SC, Fraser CG. Setting up a service for a faecal immunochemical test for haemoglobin (FIT): a review of considerations, challenges and constraints. J Clin Pathol. 2018;71(12):1041–1045. doi: 10.1136/jclinpath-2018-205047.
    1. Domènech X, Garcia M, Benito L, Binefa G, Vidal C, Milà N, et al. Cánceres de intervalo y sensibilidad de los programas poblacionales de cribado de cáncer colorrectal. Gac Sanit. 2015;29(6):464–471. doi: 10.1016/j.gaceta.2015.07.002.
    1. Benedict M, Neto AG, Zhang X. Interval colorectal carcinoma: An unsolved debate. World J Gastroenterol. 2015;21(45):12735–12741. doi: 10.3748/wjg.v21.i45.12735.
    1. McDonald PJ, Digby J, Innes C, Strachan JA, Carey FA, Steele RJC, et al. Low faecal haemoglobin concentration potentially rules out significant colorectal disease. Colorectal Dis. 2013;15(3):e151–e159. doi: 10.1111/codi.12087.
    1. Elias SG, Kok L, de Wit NJ, Witteman BJM, Goedhard JG, Romberg-Camps MJL, et al. Is there an added value of faecal calprotectin and haemoglobin in the diagnostic work-up for primary care patients suspected of significant colorectal disease? A cross-sectional diagnostic study. BMC Med. 2016;14(1):141. doi: 10.1186/s12916-016-0684-5.
    1. Mowat C, Digby J, Strachan JA, McCann R, Hall C, Heather D, et al. Impact of introducing a faecal immunochemical test (FIT) for haemoglobin into primary care on the outcome of patients with new bowel symptoms: a prospective cohort study. BMJ Open Gastroenterol. 2019;6(1):e000293. doi: 10.1136/bmjgast-2019-000293.
    1. Cubiella J, Digby J, Rodríguez-Alonso L, Vega P, Salve M, Díaz-Ondina M, et al. The fecal hemoglobin concentration, age and sex test score: Development and external validation of a simple prediction tool for colorectal cancer detection in symptomatic patients. Int J Cancer. 2017;140(10):2201–2211. doi: 10.1002/ijc.30639.
    1. Digby J, Strachan JA, Mowat C, Steele RJC, Fraser CG. Appraisal of the faecal haemoglobin, age and sex test (FAST) score in assessment of patients with lower bowel symptoms: an observational study. BMC Gastroenterol. 2019;19(1):213. doi: 10.1186/s12876-019-1135-5.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir